Feasibility of data extraction and evaluation with BeoNet-Halle: outcomes and data quality in hepatitis B and C screenings

利用BeoNet-Halle进行数据提取和评估的可行性:乙肝和丙肝筛查的结果和数据质量

阅读:1

Abstract

BACKGROUND: To support the global hepatitis strategy, the Federal Joint Committee in Germany introduced a one-time hepatitis screening within the "Check-Up 35" program on 1 October 2021. Targeting individuals aged 35 and older, this preventive check-up aims to detect common diseases early. This study examines the feasibility of using the BeoNet-Halle database to characterize patients screened for hepatitis B (HBV) and hepatitis C virus (HCV), focusing on screening volumes, billing codes, and data completeness. METHODS: We analyzed electronic medical records from all 11 practices contributing to the BeoNet network during the observation period from 1 October 2021 to 30 September 2023. The analysis focused on antibody and antigen tests, HBV-DNA and HCV-RNA tests, and billing codes (01734, 01744, 01865, 01866, 01867) to assess screening volumes, data completeness, and costs. Data completeness was evaluated by mapping the BeoNet dataset to the Medical Informatics Initiative (MII) Core Dataset. RESULTS: Of the potentially eligible population (32,213 patients aged ≥ 35), 10% underwent HBV and HCV screening as part of Check-Up 35. Screened individuals had more practice contacts (mean ± SD: 22.1 ± 19.8 vs. 11.1 ± 17.7; w = 0.3) and more chronic conditions (mean ± SD: 6.9 ± 5.6 vs. 5.8 ± 6.2; w = 0.03) than the eligible practice population. Screening identified 20 new cases (0.6%), with practice-level screening rates ranging from 2.5% to 42.6%. Billing code 01734 was documented in 81.5% of cases with laboratory test billing codes (01865-01867) missing in 5 of the 11 practice management systems (PMS). The BeoNet laboratory dataset provided full coverage for test identifiers (100%) and strong documentation of result interpretations (98.7%), but had limited coverage for reference range (60.4%) and test collection dates (9.1%). CONCLUSION: Improving data quality and billing documentation in the BeoNet database could enhance screening accuracy and resource allocation, supporting better outcomes in hepatitis screening practices.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。